Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,695.56 -987.36 (-1.60%) CMC Crypto 200
1,265.90 -17.93 (-1.40%)
ARDX Jan 2025 3.500 call
| Previous close | 3.2300 |
| Open | 3.7500 |
| Bid | 2.1000 |
| Ask | 4.5000 |
| Strike | 3.50 |
| Expiry date | 2025-01-17 |
| Day's range | 3.7500 - 3.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.21k |
GlobeNewswireArdelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Confere
Simply Wall St.When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
- GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut
